|Tested species reactivity||Human|
|Published species reactivity||Virus, Human|
|Host / Isotype||Sheep / Ig|
|Immunogen||Recombinant human interferon-beta (Hu-IFN-beta) produced in E. coli.|
|Storage buffer||whole serum diluted in PBS|
|Tested Applications||Dilution *|
|ELISA (ELISA)||Assay Dependent|
|Immunohistochemistry (IHC)||Assay Dependent|
|Immunoprecipitation (IP)||Assay Dependent|
|Neutralization (Neu)||Assay Dependent|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|ELISA (ELISA)||See 1 publications below|
Type I Interferons (IFN-alpha/beta) are produced primarily in response to viral infection by "Natural IFN-producing cells" (IPCs) as part of the host immune response and can also inhibit the development of tumors. IFN-beta binding by its receptor results in the activation of the tyrosine kinases Jak1 and Tyk2 and phosphorylation of members of the STAT family of transcription factors, leading to the transcription and expression of the immune response genes. More recently, several members of the toll-like receptor (TLR) family were found to stimulate the production IFN-beta. IFN-beta is currently used clinically for treatment of tumors, infections and multiple sclerosis.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
|TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus.||Washburn B,Weigand MA,Grosse-Wilde A,Janke M,Stahl H,Rieser E,Sprick MR,Schirrmacher V,Walczak H||Journal of immunology (Baltimore, Md. : 1950) (170:1814)||2003|